Investor Presentaiton

7 Eyes diagnosed with Glaucoma U.S. Market Opportunity 5.0 4.0 Major growth by expanding penetration in moderate patients 3.0 2.0 2.1 M 3.2 M 1.0 0.1 M 0.2 M 0.0 Severe Advanced (3+) Moderate (2-3) Mild (0-1) GLAUCOMA SPECIALIST *Market Scope and Company estimates COMPREHENSIVE . Our U.S. 2019 MP3 probes: 25K run rate Our U.S. 2019 installed systems: 800 2.4 million potential eyes in U.S. moderate + patients Over 4,000 U.S. ASC and hospital target sites 。 1,300 Glaucoma specialists 。 8,700 Comprehensive О ophthalmologists $500 Million U.S. Probe Opportunity $50M probe revenue is 10% U.S. penetration IRIDEX

View entire presentation